A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Dactinomycin has been studied across 13 research domains including 🔬 Oncology, 🫘 Kidney, ⏳ Longevity & Aging, 🫁 Liver & Detox, 😴 Sleep. The primary research focus is 🔬 Oncology with 66% of studies addressing this area.
The following compounds share molecular targets with Dactinomycin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Dactinomycin is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.